https://www.selleckchem.com/products/mmaf.html
Two patients became pregnant and underwent term cesarean delivery (25%). Conclusions NIIT can serve as an alternative pretreatment option for patients with isthmocele during IVF cycles.Background Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYNOTE-045. The aim of this study was to evaluate the oncological efficacy and safety of pembrolizumab after failu
Like
Comment
Share
